Abstract:Key PointsMuscle wasting is a debilitating condition that develops with ageing and more rapidly with inactivity (bed rest) and in various systemic diseases (for example, cancer, renal failure, chronic obstructive pulmonary disease, sepsis, HIV and trauma). Fibre atrophy primarily results from an acceleration of protein degradation, often combined with reduced protein synthesis. Treatments that prevent this activation of proteolysis or increase protein synthesis offer considerable promise to combat this debilitating process.Various types of rapid muscle wasting develop through a common transcriptional programme involving the induction of a set of atrophy-related genes (atrogenes) by forkhead box protein O (FOXO) transcription factors and reduced signalling by the PI3K–AKT–mTOR pathway.The resulting muscle weakness is a consequence of the degradation of myofibrils, which is catalysed by ubiquitin ligases that target different components of the contractile apparatus for proteasomal degradation. By contrast, the loss of endurance results from the breakdown of mitochondria via autophagy.Myostatin, an autocrine inhibitor of normal muscle growth, and its circulating homologue activin A, also trigger muscle protein loss in various catabolic states via the activation of SMAD2 and SMAD3, which function together with FOXO transcription factors.Antibodies against myostatin or activin A, or agents that block their receptor — activin A receptor, type IIB (ActRIIB) — in muscle could be a promising approach to combat muscle loss caused by cancer-associated cachexia, renal failure and ageing. Indeed, these treatments helped to preserve muscle and prolong longevity in tumour-bearing mice, and several of these treatments are currently in clinical trials.Glucocorticoids and various circulating inflammatory mediators, such as tumour necrosis factor-α (TNFα) and interleukin-6 (IL-6), have also been implicated in excessive muscle proteolysis in cachexia, but their roles in different catabolic states remain uncertain and controversial.Recent studies have increased our understanding of the biochemical mechanisms of atrophy and have identified many intracellular proteins that are crucial in muscle wasting (for example, SMADs, tripartate motif-containing protein 32 (TRIM32), nuclear factor-κB (NF-κB)) or that combat this process (for example, peroxisome proliferator-activated receptor-γ coactivator 1α (PGC1α), sirtuin1 (SIRT1) and JUNB). Their manipulation by small molecules offers many opportunities for the rational design of new treatments for this condition.

FoxP1 is a transcriptional repressor associated with cancer cachexia that induces skeletal muscle wasting and weakness

Myofiber-specific FoxP1 knockout protects against pancreatic cancer-induced muscle wasting in male but not female mice.

FOXN Transcription Factors: Regulation and Significant Role in Cancer

Role and mechanism underlying FoxO6 in skeletal muscle in vitro and in vivo

Retraction Note To: FoxM1 Down-Regulation Leads to Inhibition of Proliferation, Migration and Invasion of Breast Cancer Cells Through the Modulation of Extra-Cellular Matrix Degrading Factors

FoxO Transcription Factors Are Critical Regulators of Diabetes-Related Muscle Atrophy

The TWEAK/Fn14 signaling promotes skeletal muscle wasting during cancer cachexia

DUSP1 Promotes Muscle Atrophy by Inhibiting Myocyte Differentiation in Cachectic Patients

Forkhead Box M1 Transcriptionally Regulates the Expression of Long Noncoding RNAs Snhg8 and Gm26917 to Promote Proliferation and Survival of Muscle Satellite Cells.

Inhibition of Heat Shock Protein (HSP) 90 Reverses Signal Transducer and Activator of Transcription (STAT) 3‐mediated Muscle Wasting in Cancer Cachexia Mice

Muscle wasting in cancer

Mitochondrial fusion and altered beta-oxidation drive muscle wasting in a Drosophila cachexia model

Muscle-specific E3 ubiquitin ligases are involved in muscle atrophy of cancer cachexia: an in vitro and in vivo study.

Inhibition of HSP90 Reversed STAT3 Mediated Muscle Wasting Induced by Cancer Cachexia

Muscle wasting in disease: molecular mechanisms and promising therapies

Foxk1 Promotes Cell Proliferation and Represses Myogenic Differentiation by Regulating Foxo4 and Mef2.

Inhibitory regulation of FoxO1 in PPARδ expression drives mitochondria dysfunction and insulin resistance

Forkhead Box O Signaling Pathway in Skeletal Muscle Atrophy

Molecular and Cellular Pathobiology Dysregulated Expression of FOXM 1 Isoforms Drives Progression of Pancreatic Cancer

Over-expression of FoxO1 Inhibits the Differentiation of Porcine Skeletal Muscle Myoblast

Foxo3 Knockdown Mediates Decline of Myod1 and Myog Reducing Myoblast Conversion to Myotubes